LEGAL STANDARDS GOVERNING POST-MARKET SURVEILLANCE OF TRANSIENT GENETIC THERAPIES

1. INTRODUCTION

Transient genetic therapies are treatments designed to produce temporary genetic or molecular effects, such as short-lived gene expression, transient RNA-based modulation or temporary delivery of genetic material. Although their intended activity may be temporary, unintended immune reactions, organ toxicity, off-target effects or delayed complications may persist after treatment ends.

Post-market surveillance is therefore essential for detecting adverse events, evaluating long-term safety, updating product information and protecting patients. Liability may arise when manufacturers fail to monitor safety signals, healthcare providers neglect follow-up, or regulators and sponsors fail to respond appropriately to credible evidence of harm.

2. LEGAL AND REGULATORY FRAMEWORK

A. INDIA

The Drugs and Cosmetics Act, 1940, and the New Drugs and Clinical Trials Rules, 2019, provide the principal regulatory framework for applicable new drugs and biological products. Relevant obligations may include adverse-event reporting, pharmacovigilance systems, periodic safety update reports and risk-management activities. CDSCO administers the applicable regulatory requirements.

The precise obligations depend on the product's classification, approval conditions and applicable rules. The fact that a therapy is described as transient does not automatically exempt it from post-marketing safety obligations.

B. UNITED STATES

The Federal Food, Drug, and Cosmetic Act and Public Health Service Act provide the principal statutory framework for regulated biological products. FDA requirements concerning adverse-event reporting, safety reporting and post-approval commitments may apply according to the product and its authorisation.

The FDA's January 2020 guidance on long-term follow-up recommends risk-based monitoring for gene therapies capable of producing delayed adverse events. Its September 2025 draft guidance addresses methods for collecting post-approval safety and efficacy data for cell and gene therapies. The latter is non-binding draft guidance, not a final legal requirement.

C. EUROPEAN UNION

Regulation (EC) No. 726/2004, Directive 2001/83/EC and Regulation (EC) No. 1394/2007, where applicable, form part of the EU framework for medicinal products and advanced therapy medicinal products. Pharmacovigilance duties include safety-signal assessment, reporting and appropriate risk-minimisation measures.

3. PRINCIPAL LIABILITY STANDARDS

A. FAILURE TO DETECT OR REPORT ADVERSE EVENTS

Manufacturers and marketing authorisation holders may face regulatory action where they fail to comply with applicable adverse-event reporting obligations or required pharmacovigilance procedures. Healthcare professionals may also have reporting obligations under the applicable framework.

B. FAILURE TO CONDUCT APPROPRIATE FOLLOW-UP

Monitoring should reflect the therapy's mechanism, duration of biological activity, delivery method, known risks and uncertainties. A failure to investigate credible delayed effects may support negligence or regulatory non-compliance where a legal duty exists.

C. FAILURE TO UPDATE WARNINGS OR MITIGATE RISKS

Where new evidence changes the benefit-risk assessment, responsible parties may need to update product information, introduce additional monitoring, restrict use or take other regulatory action. Failure to act on established safety signals may support liability if the applicable legal elements are proved.

4. IMPORTANT CASE LAWS

1. Samira Kohli v. Dr. Prabha Manchanda, (2008) 2 SCC 1 — Direct Authority on Medical Consent.

The Supreme Court of India explained the requirements for valid medical consent. In genetic therapy cases, this principle is relevant to disclosure of material risks, follow-up requirements and uncertainty about the duration of biological effects.

2. Jacob Mathew v. State of Punjab, (2005) 6 SCC 1 — Analogous Authority on Negligence.

The Court explained the principles governing professional negligence. These principles may apply where a healthcare professional unreasonably ignores warning signs or fails to provide appropriate monitoring after genetic treatment.

3. Indian Medical Association v. V.P. Shantha, (1995) 6 SCC 651 — Analogous Authority on Healthcare-Service Liability.

The judgment addressed the application of consumer-protection law to medical services. It may be relevant where deficient post-treatment care or follow-up falls within the applicable consumer-protection framework.

4. Wyeth v. Levine, 555 U.S. 555 (2009) — Analogous Authority on Pharmaceutical Warnings.

The United States Supreme Court considered pharmaceutical failure-to-warn liability. The decision illustrates the importance of adequate warnings and manufacturer responsibility, although it did not concern genetic therapies or post-market gene-therapy surveillance.

5. Sanofi Pasteur MSD SNC v. OB, Case C-621/15 (2017) — Direct Authority on EU Product Liability Principles.

The Court of Justice of the European Union considered evidentiary issues in a claim alleging injury from a vaccine. It explained that national courts may assess a combination of serious, specific and consistent evidence, subject to applicable evidentiary principles. The case is relevant by analogy to proving causation in complex genetic-therapy injury claims.

6. Boston Scientific Medizintechnik GmbH v. AOK Sachsen-Anhalt, Joined Cases C-503/13 and C-504/13 (2015) — Analogous Authority on Product Defects.

The CJEU addressed product-defect principles involving implanted medical devices. Its reasoning illustrates how safety expectations and potential risks may be assessed under EU product-liability law. It does not establish a gene-therapy-specific liability standard.

5. COMPLIANCE AND PREVENTION

Sponsors should establish risk-based surveillance plans, reliable adverse-event reporting systems, periodic safety reviews and procedures for investigating emerging signals. Healthcare providers should document treatment outcomes, communicate warning signs and arrange follow-up proportionate to the therapy's known risks.

Records should include product batches, treatment dates, adverse-event timelines, laboratory findings and corrective actions. Contracts may allocate operational responsibilities, but they cannot remove mandatory statutory obligations.

6. CONCLUSION

Post-market surveillance of transient genetic therapies requires continuing assessment of safety even after the intended molecular effect has diminished. Liability may arise from negligent monitoring, inadequate warnings, failure to report adverse events or failure to implement required risk-minimisation measures. The cited judgments establish relevant principles of consent, negligence and product liability, but none creates a specific universal rule for transient genetic therapies. Compliance must therefore be assessed under the applicable jurisdiction, product authorisation and current regulatory requirements.